Aurora Financial JournalSynAct Pharma AB (SYNACT.ST)
Nasdaq Stockholm · Financial statements, TTM figures and earnings dates
In fiscal year 2024 (ended December 31, 2024), SynAct Pharma AB reported revenue of SEK 0 and net income of −SEK 82.4M. Annual financial statements are available for fiscal years 2021 to 2024, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| SEK | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 | FY2021 2021-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | SEK 0 | SEK 0 | SEK 0 | SEK 0 |
| Gross profit | SEK 0 | SEK 0 | SEK 0 | SEK 0 |
| Operating income | −SEK 90.0M | −SEK 224.5M | −SEK 105.7M | −SEK 76.7M |
| Net income | −SEK 82.4M | −SEK 215.8M | −SEK 99.2M | −SEK 69.3M |
| Diluted EPS | −SEK 2.08 | −SEK 6.64 | −SEK 3.60 | −SEK 2.68 |
| Cash flow | ||||
| Operating cash flow | −SEK 89.2M | −SEK 100.2M | −SEK 117.6M | −SEK 65.0M |
| Balance sheet | ||||
| Cash and equivalents | SEK 61.2M | SEK 62.4M | SEK 108.2M | SEK 24.0M |
| Total assets | SEK 270.5M | SEK 228.0M | SEK 142.6M | SEK 38.4M |
| Total liabilities | SEK 56.4M | SEK 51.8M | SEK 16.1M | SEK 17.5M |
| Shareholders' equity | SEK 214.2M | SEK 176.2M | SEK 126.5M | SEK 20.9M |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full SYNACT.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open SYNACT.ST financials →